An 8.27% slide to $185.29 takes roughly $35 billion off one of the market's most crowded AI names in a single session. Moves this size are where Palantir's premium multiple gets tested, so keep an eye on whether the $202 open gets reclaimed.
The Nasdaq's 2.3% drop was more than four times the Dow's loss, concentrating the damage in the crowded tech trade. Anyone overweight big tech felt this close far more than the index headline suggests.
A 7.18% slide to $12.36 leaves this ad tech name valued at just $5.3 billion, a fraction of what it once commanded.
Dow and LyondellBasell slashed their dividends while Air Products kept raising its payout, and the reason comes down to a structural difference that most yield screens completely miss.
Few companies sit closer to the race to power AI data centers than Bloom Energy (NYSE:BE). Bloom Energy shares have climbed 157% year to date (YTD) to $223.03, a run that leaves rival fuel cell stocks and the hydrogen sector well behind. The fuel cell maker has become a key supp…
When a seven-figure IRA hits the age that triggers mandatory withdrawals, chasing the yield you actually need can quietly destroy the account you spent decades building. One blended approach threads that needle, but the math behind it exposes some uncomfortable tradeoffs.
A 4.22% jump to $387.76 is a big single-day move for an $80.9 billion insurer, and it lands the same morning Travelers filed its Q3 2026 earnings. Keep an eye on whether the gain holds into the close.
A 5.21% slide to $12.47 knocks roughly $1 billion off Rivian's $18 billion market cap in a single session. Moves this size on no company-specific news tend to set the near-term trading range, so keep an eye on the stock.
A 9.57% drop wipes out a chunk of a company now worth just $1.2 billion, where every dime of the share price carries real weight. Moves this size are the norm here, so keep an eye on whether $3 holds.
A 9.94% drop wipes roughly $700 million off SentinelOne's market cap in a single session. Moves this size are rare for the name, and the opening level is now one it has to climb back to.
Eli Lilly spent most of its 150-year history as a quiet insulin maker before a single drug reshuffled the entire obesity market and turned a modest stake into a fortune that left the S&P 500 in the dust. The question now is whether the next chapter repeats that run or breaks it.
A Goldman Sachs survey found that more than a third of people earning over $300,000 still run out of money before the next paycheck, and for one of them, the gap between his working life and retirement has never actually been calculated.
